3112 related articles for article (PubMed ID: 26751436)
1. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial effects of curcumin: An in vitro minimum inhibitory concentration study.
Gunes H; Gulen D; Mutlu R; Gumus A; Tas T; Topkaya AE
Toxicol Ind Health; 2016 Feb; 32(2):246-50. PubMed ID: 24097361
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activity of tebipenem against ESBL-producing E. coli.
Thamlikitkul V; Lorchirachoonkul N; Tiengrim S
J Med Assoc Thai; 2014 Dec; 97(12):1259-68. PubMed ID: 25764632
[TBL] [Abstract][Full Text] [Related]
7. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2005)].
Goto H; Takeda H; Kawai S; Watanabe S; Okazaki M; Shimada K; Nakano K; Yokouchi H; Mori T; Igari J; Oguri T; Yamamoto M; Kudo K; Kobayashi N; Tanaka T; Yoshimura K; Kawabata M; Nakamori Y; Sumitomo M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Aoki N; Honma Y; Suzuki Y; Karasawa Y; Oka M; Kobashi Y; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Oikawa S
Jpn J Antibiot; 2008 Aug; 61(4):209-40. PubMed ID: 19024644
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial Properties and Efficacy of LL-37 Fragment GF-17D3 and Scolopendin A2 Peptides Against Resistant Clinical Strains of Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii In Vitro and In Vivo Model Studies.
Farzi N; Oloomi M; Bahramali G; Siadat SD; Bouzari S
Probiotics Antimicrob Proteins; 2024 Jun; 16(3):796-814. PubMed ID: 37148452
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial, anti-inflammatory activities and toxicology of phenylethanoid glycosides from Monochasma savatieri Franch. ex Maxim.
Liu YL; He WJ; Mo L; Shi MF; Zhu YY; Pan S; Li XR; Xu QM; Yang SL
J Ethnopharmacol; 2013 Sep; 149(2):431-7. PubMed ID: 23850835
[TBL] [Abstract][Full Text] [Related]
10. [Antimicrobial activity of tebipenem against various clinical isolates from various specimen, mainly urinary tract].
Muratani T; Doi K; Kobayashi T; Nakamura T; Matsumoto T
Jpn J Antibiot; 2009 Apr; 62(2):116-26. PubMed ID: 19673353
[TBL] [Abstract][Full Text] [Related]
11. [Antiseptic effect of compound lysostaphin disinfectant and its preventive effect on infection of artificial dermis after graft on full-thickness skin defect wound in rats].
Jin J; Zhou H; Cui ZC; Wang L; Luo PF; Ji SZ; Hu XY; Ma B; Wang GY; Zhu SH; Xia ZF
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):225-232. PubMed ID: 29690741
[No Abstract] [Full Text] [Related]
12. Design, synthesis and biological evaluation of 3-(4-halophenyl)-3-oxopropanal and their derivatives as novel antibacterial agents.
Liu J; Yi W; Hu J; Wu F; Zhao L; Song H; Wang Z
Chem Pharm Bull (Tokyo); 2010 Sep; 58(9):1127-31. PubMed ID: 20823588
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections.
McEntee L; Johnson A; Farrington N; Unsworth J; Dane A; Jain A; Cotroneo N; Critchley I; Melnick D; Parr T; Ambrose PG; Das S; Hope W
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109982
[TBL] [Abstract][Full Text] [Related]
14. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals.
Fujimoto K; Takemoto K; Hatano K; Nakai T; Terashita S; Matsumoto M; Eriguchi Y; Eguchi K; Shimizudani T; Sato K; Kanazawa K; Sunagawa M; Ueda Y
Antimicrob Agents Chemother; 2013 Feb; 57(2):697-707. PubMed ID: 23147735
[TBL] [Abstract][Full Text] [Related]
15. CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo.
Kim J; Ha JR; Oh SW; Kim HG; Lee JM; Lee DG; Lee SH; Kim JG
Biol Pharm Bull; 2007 Mar; 30(3):575-9. PubMed ID: 17329859
[TBL] [Abstract][Full Text] [Related]
16. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
[TBL] [Abstract][Full Text] [Related]
17. Contemporary Evaluation of Tebipenem
Mendes RE; Arends SJR; Streit JM; Critchley I; Cotroneo N; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0205722. PubMed ID: 36625644
[TBL] [Abstract][Full Text] [Related]
18. Searching for a potential antibacterial lead structure against bacterial biofilms among new naphthoquinone compounds.
Moreira CS; Silva AC; Novais JS; Sá Figueiredo AM; Ferreira VF; da Rocha DR; Castro HC
J Appl Microbiol; 2017 Mar; 122(3):651-662. PubMed ID: 27930849
[TBL] [Abstract][Full Text] [Related]
19. Investigations on yearly changes in tebipenem susceptibility of bacterial isolates from pediatric patients -A post-marketing surveillance of tebipenem pivoxil granules for pediatric.
Sugano T; Takata T; Senju N; Takayama Y; Ida T
Jpn J Antibiot; 2016 Aug; 69(4):265-290. PubMed ID: 30226954
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy: a way to limit emergence of resistance?
Michéa-Hamzehpour M; Pechère JC; Marchou B; Auckenthaler R
Am J Med; 1986 Jun; 80(6B):138-42. PubMed ID: 3088999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
